🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

CTFFR and Prediction of Non-Significant CAD Lesions

RecruitingNAAges 20 Years - 80 YearsAllShiraz University of Medical Sciences
NCT06979427 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

In this prospective cohort study, 250 patients with suspected or known CAD and at least one intermediate coronary lesion (50-70% stenosis) who had a NiFFR value greater than 0.80 underwent coronary computed tomography angiography (CCTA) with NiFFR assessment. Patients were followed for one year to monitor for MACE

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Patients were enrolled if they had at least one intermediate coronary lesion (classified as 50-70% diameter stenosis on visual judgment) on CCTA and then underwent FFR testing Exclusion Criteria: * Patients having past coronary artery bypass graft surgery (CABG) * previous PCI in the target vascular * significant renal impairment define with eGFR \< 30 mL/min/1.73 m² * contrast allergy * poor image quality that prevented appropriate CCTA or CT-FFR analysis
💊

What it tests

  • NIFFR
📍

Where

1 site
Professor Kojuri Cardiology Clinic
Shiraz, Iran
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy